Dysbiosis & Long COVID
The SARS-CoV-2 virus causes COVID-19, which ranges from mild initial symptoms to severe multi-organ dysfunction. While some patients recover to their baseline states, others develop a long COVID, or post-acute sequelae of SARS-CoV-2 (PASC) consisting of symptoms persisting \>2-6 months post-infection. PASC symptoms inc
| Condition(s) | COVID-19 |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The SARS-CoV-2 virus causes COVID-19, which ranges from mild initial symptoms to severe multi-organ dysfunction. While some patients recover to their baseline states, others develop a long COVID, or post-acute sequelae of SARS-CoV-2 (PASC) consisting of symptoms persisting \>2-6 months post-infection. PASC symptoms include post-exertional malaise, fatigue, and heart palpitations as well as incident GI disorders, cognitive dysfunction, and arthritis. Based on prevalence/incidence studies, it is estimated that more than 30 million people in the US have ever developed PASC with 10-11% of patients or 11 million people continuing to feel symptoms to the present day10. SARS-CoV-2 vaccines are only \~32% effective against infection at 4 months post-vaccination11, only 15% effective against the de |
| Who can participate | Inclusion Criteria: * Age: 18-80 * Sex: Any * Race: Any * Last COVID infection: within past 3 years, PCR- or antigen-confirmed, symptomatic (mild/moderate/severe) * COVID vaccination status: Any * Presence of long COVID symptoms (GI, cardiac, pulmonary, neuro, musculoskeletal, and/or psych): 200 with symptoms, 200 w/o symptoms as defined by SBQ-LCTM. * May or may not be doing routine endoscopy at UCM Exclusion Criteria: * Age \<18 or \>80 * Last COVID infection \>3 years ago (PCR/antigen-confirmed, symptomatic) * Currently or within the last 3 months COVID+ by nasopharyngeal PCR/antigen test * Currently diagnosed with cancer * Currently pregnant (cannot take colon biopsy sample; only eligible for survey/blood \& stool collection) * Currently on biologic immunomodulatory medications * Offic |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University of Chicago |
| Locations | Chicago, Illinois, United States |
| Start date | 2025-01-21 |
| NCT ID | NCT06825819 |
| Official listing | https://clinicaltrials.gov/study/NCT06825819 |